Benon Zebosi
ID:
|
Factors associated with functional capacity and nutritional status among community dwelling elderly aged 65 to 85 in Lugazi municipality, Buikwe district
REFNo: SS1031ES
1. To assess the nutritional status of the elderly persons aged 65 to 85 in Lugazi municipality, Buikwe district.
2. To assess the functional capacity of the elderly persons aged 65 to 85 in Lugazi municipality, Buikwe district.
3. To investigate the association between functional capacity and nutritional status of the elderly persons aged 65 to 85 in Lugazi municipality, Buikwe district.
|
Uganda |
2022-04-13 |
2025-04-13 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Ruth Namazzi
ID: UNCST-2020-R014305
|
Alternative Dosing And Prevention of Transfusions (ADAPT):
A prospective study to reduce transfusion requirements for children with sickle cell anemia using pharmacokinetics-based hydroxyurea dosing
REFNo: HS2093ES
Primary Objective
• To compare the rates of blood transfusions overall and by specific indications in children with sickle cell anaemia (SCA), prior to and during hydroxyurea treatment
Secondary Objectives
• To determine clinical and laboratory factors associated with reduction in blood transfusions for children with SCA on hydroxyurea treatment
• To assess the feasibility and safety of a pharmacokinetic (PK)-based hydroxyurea dose within the predicted treatment range for Uganda
• To quantify rates of SCA-related complications (including stroke, sepsis, and pain) in participants receiving PK-guided hydroxyurea dosing and within the overall cohort on hydroxyurea treatment
|
Uganda |
2022-04-13 |
2025-04-13 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Douglas Bulafu
ID: UNCST-2021-R011774
|
Adherence to Malaria Treatment Guidelines among Health Care Workers in Private Health Facilities in Kampala’s informal Settlements, Uganda
REFNo: HS2161ES
To explore barriers and facilitators towards malarial treatment guidelines among HCWs in private health facilities,To assess the factors associated with adherence to malaria treatment guidelines among HCWs in private health facilities,To establish the level of adherence to malaria treatment guidelines among HCWs in private health facilities,To assess adherence to malaria treatment guidelines and associated factors among HCWs in private health facilities in Kampala's informal settlements, Uganda,
|
Uganda |
2022-04-13 |
2025-04-13 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Rachel Nankanja Babirye
ID:
|
FIGO/AOGU Advocacy for the Prevention of Maternal Mortality and Morbidity in Uganda (APMM) due to unsafe abortion –end evaluation of a three years’ multi-country capacity building project
REFNo: SS1249ES
1. To document the results and achievements achieved by FIGO and the member societies
2. To analyse the contribution of the project in strengthening the societies and the results achieved
3. To assess the project implementation by FIGO and the member societies, including lessons learned.
4. To extract lessons learned – “understanding enabling and hindering factors in advocacy for CAC, including safe abortion within the context of the law”
|
Uganda |
2022-04-13 |
2025-04-13 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
ANNETTEE NAKIMULI OLIVIA
ID: UNCST-2022-R011194
|
Enhancing prediction of adverse pregnancy outcomes in Africa through partnerships and innovation
REFNo: HS2195ES
4. Calibrate the intersection between socio-epidemiological, clinical and laboratory parameters of the GOS using artificial intelligence.,3. To generate a resource of data and biological samples to facilitate hypothesis driven and discovery based approaches to identifying novel predictors and/or mechanisms of pre-eclampsia and the other GOS. ,2. To determine the positive predictive value of screening using biomarkers (soluble Flt-1 and placental growth factor) and serial ultrasound for the different adverse pregnancy outcomes in (1) above.,1. To determine the exposures (epidemiological, social, demographic, clinical, laboratory) linked to the different outcomes - pre-eclampsia, stillbirth, preterm birth and fetal growth restriction.,To enhance prediction of adverse pregnancy outcomes in Africa through partnerships and innovation,
|
Uganda |
2022-04-13 |
2025-04-13 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Jörg Wiegratz
ID:
|
Changing the game: The dynamics of the commercialisation of football in Eastern Africa
REFNo: SS1246ES
This project is a comparative study of the ongoing and intensifying dynamics of commercialisation of football in East Africa. The aim is to empirically investigate and map the major drivers, characteristics and repercussions (also in terms of development of football, i.e. professionalism, performance, club management, fan experience, popularity etc.) of the commercialisation in two countries: Kenya and Uganda. It aims to capture stakeholders’ experiences, insights and views concerning commercialisation of football. The overall question is: what changes are triggered by the commercialisation of local football? I will talk to various stakeholders and gain some insights into developments at different clubs and commercial developments in Kampala/the country. These case studies will allow me to explore the dynamics of introducing cutting-edge commercial models in sports leagues on a continent that has had – compared to other regions – relatively low levels of commercialisation until recently. This will enable a better understanding of commercialisation-in-practice – and respective similarities and differences across the two sites - in a key football region in the Global South. The findings will inform relevant public/policy debates in the two countries, the region generally and beyond (e.g. at global level) regarding various aspects of the commercialisation of soccer. The study will contribute to the relatively nascent literature on commercialization in Africa generally. It will also draw lessons regarding commercialisation processes and issues that might be applicable to other countries in Africa and beyond.
|
Germany |
2022-04-12 |
2025-04-12 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Julius Magala
ID:
|
Using Data to Catalyze Energy Investments
REFNo: SIR98ES
Main Objective: The overarching goal is to provide improved data on demand for productive energy use across Uganda to inform future actions/investments by the Ugandan Government as well as other stakeholders.
Specific Further Objectives: Our methods will capture data related to agricultural conditions and practices, complemented by spatial analysis. Respondent interviews will focus primarily on cropping and irrigation seasonality. These will be used in combination with numerous field observations (taken without interviews). Finally, the outputs of the CWP effort will emphasize statistical analysis and machine learning in order to make geospatial predictions, identifying areas where a combination of factors establish a higher probability for presence of and success in irrigation.
|
Uganda |
2022-04-12 |
2025-04-12 |
Engineering and Technology |
Non-Clinical Trial |
Non-degree Award |
|
Shelley Jones
ID:
|
COVID-19 as an urgent call for commitment to women's resilience and empowerment: A participatory action research project with vulnerable women in Uganda
REFNo: SS1207ES
The objectives of this project are to work with women in Uganda to develop and pilot a contextually- and culturally-responsive Resiliency and Empowerment Framework (REF) that will foster a community of support that encourages women to self-inventory their skills, knowledge, abilities, and experiences as well as identify and access resources they require to exercise empowerment and work collectively to transform their societies. The REF will be adaptable for women living in diverse contexts throughout the world. As part of REF, participants will create and implement their own, personal multi-stage Resiliency and Empowerment Plans (REPs) that will reflect their own aspirations. These REPs may represent individualistic or collaborative trajectories.
|
Canada |
2022-04-12 |
2025-04-12 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Robert Ssekitoleko
ID: UNCST-2019-R001716
|
Impacts of Covid-19 on Provision of Essential Healthcare Services and on Community Networks in Uganda
REFNo: HS2181ES
General Objective
To evaluate the Impact of COVID-19 on provision of essential Healthcare services and on the community networks in Uganda
Specific objectives
1. To determine the Impact of COVID-19 on essential health service delivery in Regional Referral Hospitals in Uganda.
2. To evaluate the actual local activities and collaboration of key stakeholders involved in CES in response to COVID-19 pandemic Uganda.
|
Uganda |
2022-04-07 |
2025-04-07 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Haruna Muwonge
ID: UNCST-2019-R000128
|
A Randomized, Double-Blinded, Placebo-Controlled, Phase III, Clinical Trial of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in Adults Aged 18 Years and Above
REFNo: HS2185ES
Safety: To evaluate adverse events from the first dose and the booster dose to Day 28 after the whole-course immunization and serious adverse events from the first dose and the booster dose to at least 12 months after the whole-course immunization,Efficacy: To evaluate the efficacy of the SARS-CoV-2 Vaccine, Inactivated (Vero Cell) for symptomatic and laboratory-confirmed (RT-PCR method) COVID-19 cases caused by different SARS-CoV-2 variants,Immunogenicity: To evaluate the immune persistence of the investigational vaccine,Immunogenicity: To demonstrate the consistency of 3 lots of investigational vaccine in terms of GMT 14 days after the whole-course immunization,Immunogenicity: To evaluate the levels of neutralizing antibody and IgG antibody against SARS-CoV-2 14 days after the whole-course and after the booster immunization,Efficacy: To evaluate the efficacy of the SARS?CoV?2 Vaccine, Inactivated (Vero Cell) against symptomatic and laboratory-confirmed (RT?PCR method) severe COVID-19 disease,Efficacy: To evaluate the efficacy of the SARS?CoV?2 Vaccine, Inactivated (Vero Cell) after at least one dose, 2 doses, and after the booster dose of immunization,To evaluate the efficacy, safety and immunogenicity of the SARS?CoV?2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above after a 2-dose schedule, and after booster vaccination,
|
Uganda |
2022-04-07 |
2025-04-07 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|